This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Chandel, Vaishali; Raj, Sibi; Kumar, Prabhat; Gupta, Shilpi; Dhasmana, Anupam; Kesari, Kavindra Kumar; Ruokolainen, Janne; Mehra, Pravesh; Das, Bhudev C.; Kamal, Mohammad Amjad; Kumar, Dhruv

Metabolic regulation in HPV associated head and neck squamous cell carcinoma

Published in:
LIFE SCIENCES

DOI:
[10.1016/j.lfs.2020.118236](https://doi.org/10.1016/j.lfs.2020.118236)

Published: 01/10/2020

Document Version
Peer reviewed version

Published under the following license:
CC BY-NC-ND

Please cite the original version:
Chandel, V., Raj, S., Kumar, P., Gupta, S., Dhasmana, A., Kesari, K. K., Ruokolainen, J., Mehra, P., Das, B. C., Kamal, M. A., & Kumar, D. (2020). Metabolic regulation in HPV associated head and neck squamous cell carcinoma. *LIFE SCIENCES*, 258, [118236]. <https://doi.org/10.1016/j.lfs.2020.118236>

Journal Pre-proof

Metabolic regulation in HPV associated head and neck squamous cell carcinoma

Vaishali Chandel, Sibi Raj, Prabhat Kumar, Shilpi Gupta, Anupam Dhasmana, Kavindra Kumar Kesari, Janne Ruokolainen, Pravesh Mehra, Bhudev C. Das, Mohammad Amjad Kamal, Dhruv Kumar

PII: S0024-3205(20)30988-7
DOI: <https://doi.org/10.1016/j.lfs.2020.118236>
Reference: LFS 118236

To appear in: *Life Sciences*

Received date: 22 May 2020
Revised date: 25 July 2020
Accepted date: 5 August 2020

Please cite this article as: V. Chandel, S. Raj, P. Kumar, et al., Metabolic regulation in HPV associated head and neck squamous cell carcinoma, *Life Sciences* (2018), <https://doi.org/10.1016/j.lfs.2020.118236>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Metabolic regulation in HPV associated head and neck squamous cell carcinoma

Vaishali Chandel¹, Sibi Raj¹, Prabhat Kumar¹, Shilpi Gupta¹, Anupam Dhasmana^{2,5}, Kavindra Kumar Kesari³, Janne Ruokolainen³, Pravesh Mehra⁴, Bhudev C Das¹, Mohammad Amjad Kamal^{6,7,8}, Dhruv kumar^{1, *}

¹Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University UttarPradesh, Sec 125, Noida -201303, India

²Himalayan School of Biosciences, Swami Rama Himalayan University, Swami Ram Nagar, Jolly Grant, Doiwala, Dehradun-248016, India

³Department of Applied Physics, School of Science, Aalto University, Espoo02150, Finland

⁴Department of Oral and Maxillofacial surgery, Lady Hardinge Medical College, New Delhi, India

⁵Department of Immunology and Microbiology, School of Medicine, University of Rio Grande Valley, McAllen, Texas, USA

⁶King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Kingdom of Saudi Arabia

⁷Enzymoics, 7 Peterlee Place, Hebersham, NSW 2710

⁸Novel Global Community Educational Foundation, NSW, Australia.

*Corresponding Author(s):

Dr. Dhruv Kumar

Email: dhruvbhu@gmail.com, dkumar13@amity.edu

Tel: +ve91 7082436598

Abstract

Cancer cells exhibit distinct energy metabolic pathways due to multiple oncogenic events. In normoxia condition, the anaerobic glycolysis (Warburg effect) is highly observed in Head and Neck Squamous Cell Carcinoma (HNSCC). HNSCC is associated with smoking, chewing tobacco, consumption of alcohol or Human Papillomavirus (HPV) infection primarily HPV16. In recent years, the correlation of HPV with HNSCC has significantly expanded. Despite the recent advancement in therapeutic approaches, the rate of HPV infected HNSCC has significantly increased in the last few years, specifically, in lower middle-income countries. The oncoproteins of High-risk Human Papillomavirus (HR-HPV), E6 and E7, alter the metabolic phenotype in HNSCC, which is distinct from non-HPV associated HNSCC. These oncoproteins, modulate the cell cycle and metabolic signaling through interacting with tumor suppressor proteins, p53 and pRb. Since, metabolic alteration represents a major hallmark for tumorigenesis, HPV acts as a source of biomarker linked to cancer progression in HNSCC. The dependency of cancer cells to specific nutrients and alteration of various metabolic associated genes may provide a unique opportunity for pharmacological intervention in HPV infected HNSCC. In this review, we have discussed the molecular mechanism(s) and metabolic regulation in HNSCC depending on the HPV status. We have also discussed the possible potential therapeutic approaches for HPV associated HNSCC through targeting metabolic pathways.

Keywords: HNSCC; HPV Infection; Glycolysis; Metabolism; Cancer therapy

1. Introduction

Despite the fact that Warburg phenomenon was first described centuries ago, however, the association between major metabolism regulators and oncogenes has fueled a renewed interest in the area of cancer cell metabolism in the last few years [1]. Although, every year with the incidence of 650,000 new cases, head and neck squamous cell carcinoma (HNSCC) has been recognized the sixth most common cancer worldwide [2]. HNSCC is classified into two subgroups, Human Papillomavirus negative (HPV⁻) and Human Papillomavirus positive (HPV⁺) HNSCC [3]. The most common cause of HNSCC malignancies includes smoking, chewing tobacco and alcohol consumption with the case of HPV⁻ HNSCC and Human Papillomavirus in HPV⁺ HNSCC (Fig.1) [4]. HPV⁺ HNSCC are commonly associated with oropharyngeal part of the Head and Neck, usually determined by the expression of p16 (surrogate marker) [5]. In corresponding to migration, invasion, and response to chemotherapy, HPV infected HNSCC has different clinical behavior, molecular and metabolic profiles [6]. The routine technique used for assessing HNSCC tumor is PET-CT scan imaging, which state the metabolic activity of the cells [7,8]. This suggests that a specific metabolic pathway may facilitate the promotion and progression of HNSCC tumor and can represent therapeutic targets. It has been reported that HPV⁺ HNSCC cells rely on mitochondrial respiration with decreased rate of glycolysis, whereas, HPV⁻ HNSCC cells depend on glucose metabolism for survival [9]. HNSCC meet their metabolic demands highly depending on the anaerobic glycolysis that helps cancer cells in rapid proliferation [10]. HNSCC cells with HPV⁺ infection gets benefited hugely by glycolysis independently of the oxygen availability where it helps the HNSCC to resist the chemotherapeutic drug as well as detoxify the free radicals. Additionally, glycolytic regulation also produces pyruvate and lactate, which promote and confer radio resistance [11]. This review primarily focusses on the basic principle and mechanism(s) of cancer cell metabolism in HPV associated HNSCC, showing differential therapeutic outcome,

which may lead to the altered metabolic activity and possible intervention(s) for the effective treatment against different subtype of HNSCC.

2. HPV in head and neck cancer

Human Papillomavirus (HPV) is a double-stranded, non-enveloped DNA virus consisting of approximately 8000 base pairs and encoding a total of 8-9 proteins. More than 100 distinct HPV genotypes are identified till date [12]. The E6 and E7 HPV oncoproteins cooperatively promote loss of cell cycle control, inhibit apoptosis, promote uncontrolled cell proliferation and induce chromosomal instability through degrading two major tumor suppressor genes, p53 and pRb [13,14]. It has become clear over the last few decades that HPV not only causes cervical cancer, but also causes a subset of HNSCC [15]. HNSCC patients with HPV infection are reportedly younger in age and also have different clinical characteristics where tobacco remains a contributor to the disease. [16]. HPV⁺ HNSCC as compared to the HPV⁻ HNSCC samples have poorly characterized histology. Additionally, the HPV⁺ tumors tend to be diagnosed at small tumor stage. Interestingly, patients with HPV⁺ status show improved performance rate and a better prognosis as compared to HPV⁻ patients (Fig.1). The continuous increase in HPV infected HNSCC cases in the last few years, is picking up people's attention globally. The epidemiology of HPV associated HNSCC is largely relying on the tumor subset and the region [17].

Among the report of 500,000 annual cases of HNSCC disease a approx. number of 85,000 is reported to be HPV⁺ which suggests that most common HPV infected tumor site is of head and neck region [18]. Studies show that HPV infection causes about 30–60% of oropharyngeal carcinoma, 12% of pharyngeal cancer and 3% of oral cancer [3]. Oropharyngeal cancer shows the most accepted site for HPV associated tumors after cervical cancer as compared to the other tumor sites of oral cavity (12%) and the oropharynx (14%) (Fig.1) [19,20]. HPV associated oropharyngeal carcinoma occurs primarily in the tonsils, back of the tongue, or in the palatine region. Recent study suggests that 62% of the tongue based tumors are HPV⁺, whereas 25% are HPV⁻ [21].

3. Genetic alterations in HPV⁺ and HPV⁻ head and neck cancer

HPV⁺ and HPV⁻ HNSCC present differences in terms of epidemiology, etiology, genetic alterations, metabolism, molecular properties and response to the treatment [22]. p53 and pRb pathways are frequently altered and inactivated in both HPV⁺ and HPV⁻ HNSCC. While the inactivation mechanism of both p53 and pRb remains quite different [23]. As described above, the inactivation of p53 and pRb is caused by E6 and E7 oncoproteins in HPV⁺ HNSCC. In contrast, p53 is highly mutated in HPV⁻ HNSCC [18,24]. The higher mutation rate in HPV⁻ HNSCC has been reported in several studies as compared to HPV⁺ HNSCC [25,26]. Other studies have reported that there is a difference in genomic aberration profile and not the mutation rate in both groups. For instance, HPV⁺ HNSCC has a higher number of mutations in genes, such as TRAF3, FGFR2/3, PIK3CA, MLL2/3, DDX3X, KRAS, E2F1; while in HPV⁻ HNSCC, TP53, MLL2, NSD1, EGFR, EPHA2, NOTCH, PIK3CA, FGFR2/3, FGFR, CUL3, CDKN2A, DDR2, CASP8, HRAS genes are mutated [27]. Certain genetic modifications are shared in HNSCC irrespective of the HPV status; however, others have been specifically related to either HPV⁺ or HPV⁻ HNSCC [28]. Comparative genomic and sequencing studies have shown the amplifications in chromosome 3q, 8q, and 20p in HNSCC. Also, chromosome arms 3p and 9p are frequently lost, whereas, 11q13 is highly amplified in HPV⁻ HNSCC [29]. Several genes like SOX2, PIK3CA and TP63 are located in the 3q26-28 region [30]. CDKN2A and CCND1 encoding p16INK4A and Cyclin D1 are located on 9p and 11q13 are associated in pRb signaling and therefore the success rate of modification is less in HPV associated HNSCC [31]. Similarly, HPV infected HNSCC samples reportedly have TP53 mutations widely while not much in HPV⁻ HNSCC [32]. In addition, EGFR and FGFR1 amplifications are observed specifically in HPV⁺ HNSCC. Contrary, 14% of deletion or 8 % of mutation has been reported in receptor-associated factor 3 (TRAF3), which is mainly involved in the innate and acquired antiviral immune response, is overexpressed in HPV⁺ HNSCC [33]. Studies in HPV⁺ HNSCC have reported

elevated levels of TpC mutation frequencies and CpG transversions in HPV⁺ HNSCC, whereas the presence of HPV infection quite likely does not affect the overall mutation rate [34].

4. Cellular metabolism in HPV infected HNSCC

Adenosine triphosphate (ATP) provide energy to the cells and that utilize through carbohydrate, protein and fat metabolism [35]. End products such as the pyruvate and acetyl coenzyme-A is the result of metabolism of glucose, amino acids and other intermediaries, such as glycerol and fatty acids. The subsequent metabolic activity of acetyl-CoA in the Tricarboxylic acid cycle (TCA) and OXPHOS cycle results in the generation of energy products such as flavin adenine dinucleotide (FADH₂), nicotinamide adenine dinucleotide (NADH), and ATP [36]. Cancer cells undergo metabolic reprogramming to obtain their energy requirements since their energy requirements differ from those of normal cells (Fig.2) [37].

4. 1. Glycolysis

As compared to normal cells, glycolysis is highly upregulated in HNSCC, despite in the existence of oxygen [1]. The alteration in the levels of expression and regulation of certain tumor suppressor genes, oncogenes, and various other glycolytic enzymes and transporters determines the regulation of glycolysis in HNSCC [38]. During aerobic condition, the cells produce two ATPs with the help of glycolysis. Whereas, TCA cycle produces 36 ATPs by utilizing pyruvate through OXPHOS. Under aerobic conditions pyruvate has the fate to produce lactate with the help of the enzyme lactate dehydrogenase (LDH-A). Apart from the less production of energy in the form of ATP glycolysis has been stated to be a major feature for cancer cell metabolism [39]. Subsequently the less utilization of pyruvate and deteriorated OXPHOS, cancer cells produce less ATP through OXPHOS. Cancer cells perform glycolysis aggressively in order to maintain energy balance. The rapid generation of energy during glycolysis promotes aggressive proliferation of HNSCC [4,36]. Certain evidence suggests the involvement of HPV in metabolic reprogramming of HNSCC.

Interaction of E6 and E7 viral oncoproteins with several cellular partners have been reported to affect biological functions [40]. Studies have also shown the association between HR- HPV, E6 & E7 and Hypoxia-inducible factor-1 (HIF-1) and its downstream gene expression [41]. HIF-1 α is a transcription factor responsible for regulating and reprogramming cancer cell metabolism, enabling tumor cells to survive via modulating glycolysis and pentose phosphate pathway (PPP). This helps in inducing angiogenesis, cell proliferation, erythropoiesis, invasion and apoptosis [42,43]. Overexpression of HIF-1 α has been reported in several solid tumors, including HNSCC [44,45]. HIF-1 is a heterodimer protein which contains two subunits namely HIF-1 α mostly regulated by oxygen and a constitutively expressing HIF-1 β subunit [9]. The protein family, prolyl hydroxylase domain (PHD) mainly functions by stabilising both the subunits of HIF-1 [11]. However, HIF-1 α is rapidly weakened under normoxia condition, because HIF-1 α is hydroxylated by PHD2, which discovers a binding site for von Hippel-Lindau (VHL) which is a tumor suppressor protein. Further, E3 ubiquitin ligase complex promotes fast degradation of HIF-1 α [46]. Under hypoxic condition, a complex formation of HR-HPV, E6 & E7 with HIF-1 α and the PHD activity is prohibited by mutated VHL. This also deteriorates the proteasomal deterioration of HIF-1 α via ROS and NOS which accumulates and stabilizes the HIF-1 α subunit [47]. After HIF-1 α complex is stabilized this subunit specifically binds to the hypoxia response elements (HRE), which may present in the promoter site of target genes. This stimulates transcription of multiple genes, which has been associated within glucose metabolism, such as hexokinase (Fig.3) [48], glucose transporters (GLUT1 and GLUT3) [49,50], lactate dehydrogenase (LDH) [51], phosphoglycerate kinase [52], Na⁺/H⁺ exchanger 1 (NHE1) and carbonic anhydrase IX (CAIX) [11].

HNSCC associated with HPV has favorable outcomes as compared to the HPV⁻ [53]. It has been observed that in HPV⁺ HNSCC, a differentially regulated metabolic machinery is shown to play a major role [54]. Additionally, HIF-1 α has been reported as an important hypoxia biomarker in radioresistance and crucial metabolic regulator in cancer cells [40]. In 2017, Jennifer et al., have

reported the higher expression of HIF-1 α in HPV⁺ HNSCC as compared to HPV⁻ in normoxia condition [55]. This was followed by the correlation between HPV16-E7 and HIF-1 α . This suggests that there is a positive association between the expression of HPV and HIF-1 α . Under hypoxic condition, upregulation of HIF-1 α in both HPV⁺ and HPV⁻ HNSCC cells has been reported. However, the absolute increase in protein and hypoxia expression signal was higher in HPV⁺ cells as compared to HPV⁻ [41]. HIF-1 α activates transcription of glycolytic enzymes as well as glucose transporters, leading to an aggressive tumor behavior [56]. Rodolico et al., in 2011 stated in his findings that there is a steady linkage between the formation of HPV16-E7 and HIF-1 in HPV16 infected oral squamous cell carcinoma tissue specimens collected from 62 randomly selected patients who underwent surgical resection [57]. As discussed above, HIF-1 α binding to the HRE promoter region stimulates the transcription of multiple genes associated with glucose metabolism. HIF-1 α increases the expression of glucose transporters. This leads to an increase in glucose uptake and induces phosphorylation of glucose by increasing the activity of HK-II activity [58]. The entire pathway of glycolysis is regulated by HIF-1 α via upregulating the major enzymes responsible for glycolysis such as HK-II, LDH-A and phosphofructokinase1 (PFK1). Furthermore, upregulation of these glycolytic enzymes, favours the utilisation of glucose in glycolysis and export of lactate into the extracellular space. This promotes the tumor cell angiogenesis and survival [59]. Hence, HIF-1 α is a major pathway causing metabolic alteration in HNSCC. Because under normoxia, non-metastatic HNSCC cells utilise less glucose and HIF-1 α , suggesting that HIF-1 α dysregulation may induce warburg effect. The development of [¹⁸F]fluorodeoxyglucose positron emission tomography imaging (FDG-PET), co-ordinated with recent findings has been shown to have been associated with aggressive cancer phenotypes [60]. Therefore, it is very important to investigate the role of HIF pathway in HPV⁺ associated HNSCC to provide an insight for the development of potential therapeutic strategies.

p53 is a tumor suppressor gene and is found to be mutated in various cancers, including HNSCC. Also, p53 is reported to be a major regulator of metabolic mechanism such as glycolysis and OXPHOS [61]. Degradation of p53 by HR- HPV-E6, mediates metabolic reprogramming in HNSCC [15]. The highly important cell nutrients, which may synthesize carbon sources and macromolecules in the cells, do not freely diffuse through the lipid bilayer and are hydrophilic. These molecules need specific transporters present in the cell membrane to pass through. For instance, GLUT facilitate the entry of glucose in the cell [62,63]. Additionally, oncogenes including RAS, Myc and SRC induce the overexpression of GLUT1 and GLUT3 to maintain the Warburg phenomenon and mediate the entry of glucose in the cell (Fig.5) [64]. GLUT-1 upregulation provides several metabolic advantages to cancer the cells helping them into energy and biomass production for their survival. Also, GLUT-1 expression leads to the production several glycolytic intermediates which are further utilized by other metabolic pathways such as PPP, nucleotide production or synthesis of lipid [64]. A huge interpretation of GLUTs has been shown in the majority of cancers including HNSCC. The transcriptional regulation of p53, represses GLUT1 and GLUT4 indirectly, and limiting the uptake of glucose in the cancer cells, therefore, weaken their growth [65]. HR-HPV-E6 mediated degradation of p53, upregulates the expression of GLUT1 & GLUT4, and therefore elevate glucose uptake [66]. SGLT Na^+ /glucose co-transporters through $\text{Na}^{+ve}/\text{K}^{+ve}$ ATPase secondary active transport mediate glucose internalization in epithelial cells, which is coupled to Na^{+ve} entry. The low concentrations of glucose, SGLT1 Na^{+ve} /glucose co-transporters present in HPV⁺ HNSCC facilitates glucose accumulation [67]. HPV⁺ HNSCC shows significant over-expression of GLUT1 in HNSCC, correlating with the highest accumulation of FDG and thus higher uptake of glucose (Fig. 4). However, HPV⁺ patients have a significantly better disease free survival rate as compared with the HPV⁻ HNSCC patients [68]. GLUT1 upregulation in HPV⁺ tumors has been observed in central locations. In HPV⁻ tumors, the expression of GLUT1 was either indifferent within the nests of solid tumor or overexpression was observed at the

margins, and decreased in central location [69]. The mRNA expression level of GLUT1 was significantly higher in HPV⁺ HNSCC cells as compared to HPV⁻. Additionally, Warburg effect is enhanced by HPV16-E6 & E7 oncoproteins, which interact with HIF-1 α and promote its degradation by VHL, which significantly upregulates the expression of GLUT1 [47].

Hexokinase-II (HK-II) is a rate limiting enzyme of glycolysis, converts glucose to glucose-6-phosphate (G6P) in many tissues, such as adipose and muscle [70]. The regulation of glycolysis by HPV mediated upregulation of HK-II, facilitates the promotion of cancer cell survival, associated with poor prognosis [71,72]. Four isoforms of HK has been reported, among which the upregulation of HK-II is highly observed in the majority of cancers including HNSCC. HK-II mediates the stimulation of aerobic glycolysis and play a major role in generating building blocks for tumor cell growth [10]. Additionally, HK-II supplies intermediate metabolites and stimulates TCA cycle by utilizing glutamine derived carbon in anaplerosis [73]. Moreover, HK-II regulates autophagy by suppressing proapoptotic molecules Bax and Bad at the outer mitochondrial membrane. It plays a critical role in metabolism through integrating apoptosis and glucose metabolism [52,73,74]. Also, interaction of HK-II with VDAC (voltage dependent anion channel), outer mitochondrial pore-forming protein supply cellular ATP by coupling OXPHOS and glycolysis [75]. The VDAC/HK-II interaction blocks apoptosis through multiple mechanisms [76], such as by disturbing the pore formation of mitochondrial permeability transition [77] and by proapoptotic protein inhibition, which targets outer mitochondrial membrane [78]. Several studies have shown the potential of HPV oncoproteins, E6/E7, to induce expression of HK-II [79]. It is interesting, since it provides a direct link between the HPV oncogenes and the expression of major cellular enzymes responsible for apoptotic resistance and metabolic reprogramming in cancer cells. This leads to the increased oncogeneicity and decreased therapeutic sensitivity in the clinic [40]. Certain studies have stated that PI3K/Akt pathway is utilised via the HK-VDAC disruption which ultimately results in apoptosis. However, glycolysis may produce an enhanced levels of lactic acid

and which facilitates the tumor cells to outbreak from the detection of the immune system and allow rapid proliferation [80]. It has been reported that HPV mediated stimulation of HK-II are dependent on the overexpression of E6/E7 oncoproteins [81,82]. Two major mechanisms are involved in HK-II stimulation by HPV. First, repression of HR-HPV16 results in downregulation of the MYC transcript [83] and protein levels, thereby repressing the transcription of HK-II [84]. Overexpression of HR-HPV-E6 in Mouse Embryonal Fibroblast (MEF) associated the upregulation of HK-II expression through Myc [79]. Furthermore, stabilization of c-Myc by HR-HPV-E6 increases its protein turnover. Second, the expression of miR-143-3p is significantly induced by E6/E7 repression, suggests that HK-II inhibitory miRNA is downregulated by the induction of E6/E7. Both the mechanisms result in HK-II stimulation by HR HPV-E6 expression in HNSCC and cervical cancer cells [73]. Additionally, HR-HPV-E6 mediated p53 degradation regulates the transcription of HK-II by binding to its promoter region along with changes in the concentration of glucose, and oxygen [85]. c-Myc is a transcription factor which is reported to be a factor that interacts with HR-HPV-E6 and promotes the expression of glycolytic genes such as HK-II, LDH-A, GLUTs, enolase A and phosphofructokinase (PFK) [86,87]. In HPV⁺ and HPV⁻ HNSCC, the enhanced glycolysis is promoted by the upregulation of HK-II, which acts as a precursor as well as provides energy for the growth of the tumor [88]. In HPV⁺ HNSCC, Zeng Q et al., (2017) has reported the upregulation of HK-II, leading to enhanced glycolysis in a c-Myc-dependent manner when there was an ectopic over-expression of HPV16-E6/E7 in mouse embryo fibroblasts [89]. This suggests that the oncoproteins E6/E7 directly activates HK-II expression and is responsible for the reprogramming of HPV transformed cells to regulate glycolysis [81]. Along with this, in HPV⁻ HNSCC anaplerosis, HK-II plays a major role in carbon utilization derived from glutamine, thus, supplying intermediates for the Krebs cycle and facilitates the maintenance of homeostasis by inducing autophagy in response to glucose deprivation [75].

Lactate dehydrogenase A (LDH-A) enzyme is responsible for catalyzing the final step of anaerobic glycolysis by converting pyruvate to lactate. LDH-A is shown to be highly upregulated in HNSCC [37]. There are five known active isoenzymes of LDH present in a human. LDH-A and LDH-B encode 2 extensive subunits A and B. LDH isoenzymes efficiently catalyze pyruvate to lactate if there are more A chains than B. Conversely, excess of B chains gives the advantage to catalyze pyruvate to acetyl-CoA. Conversion of pyruvate into lactate leads to the reduction of NADH to NAD^+ , which is again reused in the glycolytic cycle and drive the process of glycolysis in cancer cells. LDH-A is a major enzyme involved in maintaining the glycolytic phenotype in cancer cells [90]. Study shows that Myc oncogene regulates the expression of LDH-A [91]. Inhibition of LDH-A in HNSCC cells by siRNA has shown to reduce the growth of tumor [92]. This suggests that inhibiting LDH-A activity could be important and effective anti-tumor therapy [93]. The incidence of aggressive tumor behaviour could be explained by the accumulation of lactate even in the presence of oxygen (Warburg effect) by LDH-A [94]. This creates an intracellular acidic environment for cancer cells mediating secretion of metalloproteinases and hyaluronidase resulting in matrix degradation by tumor associated fibroblasts (TAF) [95,96]. Additionally, the accumulation of lactate by LDH-A inhibits the activity of T Cells and dendritic cells contributing to the immunologic escape for HNSCC cells and thus inducing angiogenesis [97,98]. The tumor suppressor genes p53 and pRb gets inactivated after coming in contact with HPV oncoproteins, E6 and E7, which successfully modulates the metabolic machinery in HNSCC [99]. HPV-E6 oncoprotein facilitates the activity of mammalian target of rapamycin (mTOR) signalling pathway [100]. The accumulation leads to the induction of Warburg phenomenon by enhancing the glycolysis rate and LDH-A elevation, and lactate production [68]. Also, HPV-E7 oncoprotein leads to the induction of pyruvate kinase M2 (PKM2) isoform by acetylation and therefore promotes conversion of pyruvate to lactate by LDH-A. Additionally, HR-HPV-E2 oncoprotein promotes the HPV genome integration into host cell genome, and interact with the mitochondrial membrane. This

results in the production of reactive oxygen species (ROS). The generation of ROS positively correlates with the production of lactate by LDH-A [101]. This observation suggests that HPV associated infection in HNSCC cells leads to an acidification in the tumor microenvironment. In HPV⁻ HNSCC, the conversion of pyruvate to lactate by LDH-A creates an intracellular acidic environment by the accumulation of lactic acid inside the tumor cells and thus activates transforming growth factor- β (TGF- β), vascular endothelial growth factor (VEGF), and interleukin (IL), [102] even under normoxic conditions. It was reported that in HPV⁻ HNSCC cells (SCC-25, UMSCC89); there was a significant upregulation of LDH-A as compared to HPV⁺ HNSCC cells (UD-SCC-2, UPCI:SCC90) [103]. This suggests targeting these metabolic pathways could represent a promising therapeutic strategy for HPV associated HNSCC.

4.2. HPV in glutamine and TCA cycle

The tricarboxylic acid (TCA) also known as Krebs cycle is a central metabolic pathway responsible for redox balance and macromolecule synthesis. Various enzymes involved in Krebs cycle, such as isocitrate dehydrogenase (IDH), aconitase (aconitase hydratase), succinate dehydrogenase (SDH), fumarase (FH), α -ketoglutarate dehydrogenase complex (KGDHC) are deregulated and mutated in the majority of cancers including HNSCC [91,92]. Data suggest that targeting TCA can pave a new pathway to generate new therapeutic invention for treating cancer [104]. To meet the energy needs, cancer cells also utilize other fuel sources besides glycolysis such as glutamine to feed the TCA cycle [105, 106].

In HPV⁻ HNSCC, apart from glucose, another major source essentially playing role to fuel TCA cycle is amino acids [107]. Amino acids before entering into the TCA cycle is converted into the intermediates of α -keto acid: either oxaloacetate, pyruvate, acetyl-CoA or succinyl-CoA. The amino acid found in abundance in the human body is glutamine, which plays a major role in nitrogen transport in plasma membrane for biosynthesis of fatty acids and non-essential amino

acids, such as purines and pyrimidines, or entering the TCA cycle in the form of α -ketoglutarate (α -KG) [108]. The process of glutaminolysis i.e. the conversion of glutamine by glutaminase (GLS) to glutamate complements provides high energy cofactors [109]. Due to upregulated glycolysis and conversion of glucose to lactate in head and neck cancer, HNSCC cells (HN30 and HN31) utilize anaplerotic reactions to replenish the intermediates of TCA cycle via glutaminolysis. For doing so, cancer cells are responsible for upregulating both glutamine transporters as well enzyme catalyzing glutaminolysis [110]. HR-HPV-E6 oncoprotein degrades the p53 through proteasomal degradation [111]. p53 is a tumor suppressor which regulates cellular metabolism via the regulation of glycolysis and OXPHOS by the transcriptional activation of its downstream gene, *Tp53*-induced glycolysis and apoptotic regulator (TIGAR) [65]. p53 also activates the expression of proteins, such as the oxidase 2 (COX2), cytochrome c, ferredoxin reductase (FDR) and apoptosis-inducing factor (AIF), which facilitate mitochondrial integrity [112,113]. p53 activates OXPHOS in cancer cells via the inactivation of pyruvate dehydrogenase kinase 2 (PDK2). PDK2 is an enzyme responsible for the inhibition of pyruvate dehydrogenase complex (PDC). The PDK inhibition in cancer cells, induces the production of acetyl-CoA via PDC, an essential molecule in Krebs cycle [114]. p53 has been reported to play a critical role in glutamine metabolism pathway, an alternate path that feeds the Krebs cycle. Thus, p53 degradation by the HR-HPV-E6 oncoprotein plays a critical role in reprogramming tumor cell metabolism [115].

4.3. HPV and oxidative phosphorylation

The powerhouse of the cell, mitochondria is the centre for generating ATP [113]. Mitochondria plays important role in cell death and signalling through regulating multiple processes like OXPHOS, β -Oxidation of fatty acid and other aspects such as biogenesis, fusion and fission [116]. Therefore, the involvement of mitochondria is critical in cancer which helps the cells to adjust themselves according to their metabolic requirements. In addition, mitochondria play a major role in the treatment of cancers. It has been reported that HPV⁺ HNSCC cells (UP90 and UP154) favour

mitochondrial respiration over glucose metabolism, because of the elevated levels of cytochrome c oxidase (COX), a respiratory related enzyme and the high ratio of COX/HKII (Fig.5) [10]. However, HPV⁻ and p53 mutated HNSCC cells favour glycolysis as compared to OXPHOS for their survival [79]. The HR-HPV-E2 oncoprotein is a negative regulator of E6 and E7 [117]. Whereas, the E2 protein aggressively moves between the nucleus and cytoplasm. The position of E2 protein majorly determines the incorporation of HPV genome to the host. As reported earlier, E2 protein can induce apoptosis in cytoplasm and DNA breaks and chromosomal instability in nucleus [118]. It was reported that mitochondrial membrane also contains E2, which changes the cristae morphology and enables elevated release of ROS, which leads to the modification in cellular respiration [119]. Mitochondrial ROS production is majorly mediated by proteins from complex III and ATP synthase, which regulates the cristae structure. Consequently, E2 protein could modulate the mitochondrial function and ROS release via the interaction with these proteins [119]. It has been reported that co-expression of E2 and E1 proteins negatively regulates of glutathione levels and superoxide dismutase levels through increasing the ROS levels in tumor cells [120]. Recently, the upregulation of CAIX in HPV⁻ as compared to HPV⁺ also reported in HNSCC cells. CAIX has also been shown to reduce cell adhesion mediated through E-cadherin mediated- β -catenin axis in HNSCC [121].

5. mTOR, Akt and Myc regulation in HPV infected HNSCC

The HPV-E6 oncoprotein is responsible for promoting high metabolic phenotype through increasing the activity of mTOR [122]. mTOR is highly upregulated and associated with metabolic dysregulation in HNSCC (Fig.5). mTOR increases the expression of PKM2, PDK1, HIF-1 α , LDH and GLUT1 [74]. These pathways play important role in altering the function of cellular metabolism, which is directly mediated by HR-HPV-E6 & E7. It has been demonstrated in many studies that mTOR signalling is activated/upregulated in >80% of HNSCC. Over activation of mTOR results in the increased glucose uptake and uncontrolled glycolysis regulation in HNSCC,

which results in the increase in lactic acid production [108,109]. The expression of HR-HPV-E6 & E7 in HPV infected cells promotes the destabilization and degradation of p53 and pRb which leads to the initiation and propagation of cancer. With the help of signalling pathways such as PI3K/Akt/mTOR, these oncoproteins alter various cellular and molecular events [32]. The radiation sensitivity of HPV⁺ HNSCC also correlates with Akt activation [123]. Studies have shown that the mTOR inhibitor CCI-779 plays a key role in inhibiting proliferation of HNSCC cells and tumorigenicity when combined with external radiation therapy (XRT) as well as chemotherapeutic agents. The transcriptional activity of p53 is linked with overexpression of Myc and increased expression of HK-II, which is closely linked with enhancing glutaminolytic flux via glutamate dehydrogenase [124].

In HNSCC, p53 also dysregulate the glycolysis and energy supply through GLUT1 and GLUT4 [65]. It has been reported that p53 can also suppress the transcription and expression of GLUT3 through blocking NF- κ B activation [125]. TIGAR is a downstream target of p53 and have an enzymatic activity similar to the bi-functional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2), which is responsible for the degradation of fructose-2,6-bisphosphate (Fru-2,6-P₂) [126]. Fru-2,6-P₂ allosterically activates PFK1, rate limiting enzyme in glycolysis. Therefore, p53 leads to the downregulation of Fru-2,6-P₂ via TIGAR, thereby deactivates PFK1 and inhibits the flow of glycolysis in HNSCC cells. Additionally, p53 plays a major role in PPP by inhibiting it in a glucose 6-phosphate dehydrogenase (G6PD)-dependent manner [127]. PPP is correlated with the biosynthesis of nucleotides through involving p53 in restricting the tumor growth by limiting the nucleotides supply required for DNA replication during cell division. Whereas, the mutant p53 have been reported to play an important role in the upregulation of HIF-1 α , resulting in the increased glycolysis, fibrosis, angiogenesis contributing to cancer progression (Fig. 6) [128].

The transcription network of c-Myc is linked to majority of biological processes such as cellular growth and proliferation, development, cell cycle, apoptosis and energy metabolism. It has been reported that HPV-E6 and Myc binds to the DNA and modulates cell proliferation and cell differentiation through activating the telomerase reverse transcriptase (Fig.5) [86]. In majority of cancers, including HNSCC, the frequent dysregulation of Myc alters cellular metabolism and induce new blood vessels formation through HIF-1 signalling [84]. The specific markers responsible for alteration in HNSCC such as HK-II, PDK1, LDH and VEGF are targets of HIF-1 and are regulated by c-Myc [117, 118]. Myc is also responsible for transcriptionally activating the key enzyme regulating glutaminolysis is and TCA cycle. Myc promotes glutamine import into the cells through upregulating glutamine transporters, such as ASC amino acid transporter 2 (ASCT2) and system N transporter (SN2) [129]. Myc also converts glutamine to glutamate through activating glutaminase (GLS1) via transcriptional suppression of its negative regulator miR23a/b [130]. It plays major role in oxidation of fatty acids and metabolites into the TCA cycle through overexpression of fatty acid transporters such as fatty acid-binding protein 4 and hydroxyacyl-CoA dehydrogenase [131].

6. Impact of the oral microbiome on oral cancer

The oral microbiota plays crucial role in the human health. It maintains and controls the balances between host and microbes in oral cavity. Disbalances in the association between microbes and host in oral cavity leads to the development of oral disease. This is generally caused by bacteria and viruses that can eventually lead to the development of cancer [132]. Combination of smoke, viral infection (HPV), poor oral hygiene, alcohol consumption enhances the risk of OSCC. Research shows tobacco consumption and viral infection modulates the oral microbiota profile. Stewart et al., 2018 showed the effect of tobacco consumption and use of electronic cigarettes (EC) on the oral microbiome. It was observed that use of EC had no certain effects on the oral microbiome. However, consumption of tobacco and constant smoking had a significant effect on the resident

bacterial population on the oral microbiome. Also, tobacco consumption resulted changes in the sputum microbiota [133]. In another study, Sharma et al., 2020 identified DNA damage in the oral cavity at much higher rates in persons with high tobacco consumption. The smoke in tobacco results in exposure to carcinogens and toxic constituents, and further development of malignancies such as oral cancer. The tobacco specific two carcinogens, nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N-nitrosonornicotine (NNN) have been shown to trigger alterations that interfere with the replication, transcription, and DNA repair machinery in the oral microbiota. The altered oral microbiome due to tobacco consumption can cause disruption of host cell defense mechanisms, causing chronic inflammatory conditions resulting in a cascade of changes causing DNA damage [134]. Smoking can also result in disruption in the structure of microbial biofilm in the oral microbiome and can cause unstable colonization, rising the susceptibility to bacterial infections in smokers by modulation of innate and adaptive immunity. Additionally, smoking can result in disruption of commensal niches. Furthermore, studies have revealed the involvement of *Streptococcus spp.* as a cofactor in the transformation of oral keratinocytes by HPV resulting in malignancy. The infection of *Mycoplasma* also enhances the HPV infection rate in the oral microbiota. This resulted in modulation of glutamate metabolism, and metal transport triggering the infection [135]. However, the effect of the virus and its potential role in the metabolic activation and alteration of oral microbiome is still unclear and needs further investigation. The chronic infection constitutes the major factors responsible for cancer pathogenesis, manifesting the resident microbiota which regulate oral surrounding homeostasis [136-138]. The changes in oral microbiota modulate the association between human diseases and oral microflora. Oral microbiota seems to modulate oral carcinogenesis via modulation of cell metabolism, for example modifying the vitamins and nutrients constituents, thereby increasing the production of various cytokines known to play a critical role in various pathological conditions [139]. The upregulation of several inflammatory markers and cytokines result in the alteration of various metabolic pathways which

ultimately result in cancer progression. For example, the protein expression of RAGE changes significantly after periodontal infection caused by oral microbiota which leads to carcinogenesis [140]. Additionally, viruses such as HPV and gram negative bacteria, secrete IL-6, TNF- α by binding to leucocytes TLR receptors. These inflammatory markers supports tumor spread by creating a pro-angiogenic environment [141]. In the oral microbiome, the chronic infection caused by virus or bacteria result in metabolic changes such as sulfur compounds, free radicals, and acid generation [142]. Also, certain bacteria can metabolize alcohol to acetaldehyde that leads to genotoxicity and consequently neoplastic transformation. Furthermore, L-tryptophan metabolism in the oral microbiome to secondary metabolites such as pyruvate, indole have been shown to be associated with cancer progression. Another mechanism by which microbiota modulates the host miRNAs expression is by the production of various metabolites that results in significant changes in the metabolism of host-cell. This results in gene alteration and changes in the miRNA expressions which favors again the OSCC progression [143-145].

6. Therapeutic approach for targeting HPV⁺ and HPV⁻ HNSCC

Metabolic alteration in solid tumor is considered as a potential therapeutic target. Since cancer cells have an enhanced rate of proliferation, they follow the Warburg phenomenon to compensate their need for energy. Blocking the Warburg phenomenon by one or the other mechanism leads to the death of cancer cells selectively [144]. Additionally, it has also been demonstrated that the majority of cancer cell has functional mitochondria irrespective of the earlier known evidence that the mitochondrial activity is disrupted in cancer cells [22]. Glycolysis as well as functional mitochondria facilitate tumorigenesis in cancer cells. Earlier, it has been demonstrated that there is an explicit difference between HPV⁺ and HPV⁻ HNSCC. Also, it has been shown that the prognosis rate of HPV⁺ HNSCC is better as compared to HPV⁻ in response to the radiation treatment [145]. This clear difference facilitates the recognition of HPV⁺ and HPV⁻ HNSCC as two separate diseases. Despite the fact, both HPV⁺ and HPV⁻ HNSCC are treated in a similar manner. HPV⁻

tumors have shown to be highly glycolytic than the HPV⁺, making it clinically more helpful to find novel targets for the HPV based subtypes of HNSCC. A major issue during the treatment process is the occurrence of toxicity. Therefore, gradually, nowadays research is focusing on developing new and innovative therapeutic strategies to improve the outcomes especially focusing on the cases of HPV⁺ patients and with the aim of raising standard therapeutic strategies for HPV⁻ patients. Irrespective of enormous studies, there is still no effective cure for HPV related diseases. There are three vaccines available against HPV: Gardasil, Gardasil 9 and Cervarix [146], which can be used to prevent HPV associated cancers. Several components and drugs have been analyzed against the E1 and E2 viral proteins that are necessary for HPV genome replication (Table 1) [147].

In addition, targeting the viral genome is one other alternative effective approach towards the HPV infected treatments. One such compound belongs to the pyrrole-imidazole, which binds to the DNA Sequence specifically and targets the viral genome [148]. These compounds bind to AT-rich regions in the origin of HPV replication region where E1 and E2 binding sites are located, this affects the stability of episomal viral genomes. Also, antibody for epidermal growth factor receptor (EGFR) and radiation is considered as an alternative for HPV⁺ HNSCC [149]. Axalimogene filolisbac (AXAL or ADXS11-001) is a novel immunotherapeutic based drug which is currently being used against HPV associated HNSCC [150,151]. The use of inhibitors targeting mitochondria is a possible consideration to treat HPV⁺ HNSCC metabolism. Phenformin/metformin, for example besides activation of the PI3K pathway, inhibits Complex I of electron transport chain (ETC) and Krebs cycle intermediate in HNSCC cells [152]. Christopher T. Lucido et. al., (2018) demonstrated the expression of β 2AR that was correlated with the enhanced mitochondrial metabolism in HPV⁺ HNSCC as compared to HPV⁻ HNSCC. Targeting β 2AR with β -blockers, such as propranolol has been shown to inhibit primary tumor growth in HPV⁺ HNSCC cells [153,154]. Also, VLX600 has been shown to reduce mitochondrial metabolism in tumor cells, which along with DCA (glycolytic inhibitor) has been proven as an effective therapy against HPV⁺

HNSCC metabolism through targeting mTOR signaling [155]. On the other hand, since glycolysis is enhanced significantly in HPV⁻ HNSCC as compared to HPV⁺, anti-glycolytic drugs are considered as the best way for chemotherapy as to enhance the antitumor response rate. In 2008, Simons et al., reported the cisplatin cytotoxicity in HNSCC xenografts, which is mediated by 2-Deoxy-D-glucose (2-DG) [156]. Additionally, 3-bromopyruvate (3-BP) and lonidamine are the most commonly tested inhibitors against HK-II and are used in both pre-clinical as well as clinical model either in combination or alone with radiation therapy and chemotherapy [157]. 3-BP is responsible for inhibiting glycolysis by disrupting the connection between the outer membrane of mitochondria and HK-II, causes the deactivation of HK-II. It has been demonstrated that HK-II inhibition by using siRNA and a targeted HKII-VDAC complex induces apoptosis in cancer cells [158]. Tyrosine kinase (TK) inhibitor, for example imatinib, decreases glycolysis, hampers various glycolytic enzymes such as Hexokinase and Phosphofructokinase 1 via HIF-1 [114]. Recently, Zhang et al., 2017 reported the role of miR-143 in oral cancer and identified HK-II as a direct target of miR-143 in patients' tumor and oral cancer cells, suggesting that inhibiting HK-II by miR-143 might be a therapeutic approach for treating oral cancer (Table 1) [159].

Combinatorial effect of 2-DG with 6-aminonicotinamide, a PPP inhibitor results in increased cytotoxic effect, which proposed a new theory of targeting multiple metabolic pathways which could effectively treat the disease cancer [160]. This suggests that glycolysis via PPP plays an important role in contributing the tumorigenicity in HNSCC. AZD3965, most effective MCT1 inhibitor is currently under clinical trial phase I and has been shown to decrease the growth of the tumor by inhibiting the release of lactate and has been an effective drug for HPV⁺ HNSCC. Cetuximab inhibits proliferation of HPV⁻ HNSCC cells through inhibiting glycolysis via LDH-A by downregulation of HIF-1 α , therefore reversing the Warburg phenomenon which is critically important for the survival and proliferation of cancer cells [161]. Inhibitors, such as orlistat, blocks

the synthesis of fatty acids via fatty acid synthase which might be another effective approach to enhance the treatment response towards HPV associated HNSCC (Table 1) [162].

Tumor cell metabolism is being highly studied as a novel area for new biomarkers and assumed to be key targets for novel pharmacologic interventions. New metabolic targets continue to be identified in different types of tumor. Altogether, there is convincing evidence that HNSCC requires elevated rate of glucose uptake and conversion for cell survival and progression. This appears to make HNSCC susceptible to targeted therapies employing inhibitors to glycolytic genes or enzymes. Even the understanding of increased glycolysis mediating secondary energetic pathways such as glutaminolysis, Pentose Phosphate Pathway, serine pathway provides new targets to be inhibited for disease treatment. Identifying the key factors involved in oncogenic events and behind altered HNSCC metabolism may have important therapeutic implications.

7. Conclusions and prospective

Cancer cell metabolism plays important role in survival and progression with the help of major metabolic pathways that produce energy. So, this process of metabolic reprogramming has made its way into the hallmark of representing the disease. In head and neck cancer, HPV plays critical role in modulating their metabolism, thereby facilitating the tumor progression. The HPV oncoproteins, E6 and E7, regulate several enzymes, which are involved in metabolic pathways in HNSCC. The altered metabolism in HNSCC, provides sufficient ATP through glycolysis, which helps in meeting the high-energy demands of HNSCC during cell proliferation, migration and invasion. Additionally, the E6/E7 oncoproteins, alter several signalling pathways including mTOR, Akt, c-Myc, HIF-1 etc., which in turn alter the metabolic phenotype in HNSCC. Although, there are invasive treatments available such as larger excision procedures, cryotherapy, electrosurgery, laser therapy etc. but not all HPV+ HNSCC respond properly to the treatment apart from it they acquire the ability to resist such chemotherapeutic strategies. This suggests that there is an urgent need of development of new

strategies to overcome these issues. Therefore, focussing on cancer cell metabolism associated with HPV status could effectively bring out new therapeutic development which could be helpful to manage the disease.

Conflict of interest statement

The authors declare there is no conflict of interest.

Acknowledgements

We thank our lab members and collaborators for carefully reading the manuscript and contributing valuable inputs for improving the manuscript. S.R. and D.K. were supported by the Department of Science & Technology- Science and Engineering Research Board (DST-SERB) funded research grant (ECR/2016/001489), Govt. of India.

References

1. V.C. Sandulache, J.N. Myers, Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets, *Head Neck*. 34 (2) (2012) 282-90. DOI:10.1002/hed.21664
2. N. Vigneswaran, M.D. Williams, Epidemiological trends in head and neck cancer and aids in diagnosis, *Oral Maxillofac. Surg Clin North Am.* 26 (2) (2014) 123-41. DOI:10.1016/j.coms.2014.01.001
3. K. Kobayashi, K. Hisamatsu, N. Sumi, A. Hara, H. Tomita, T. Miyazaki, A Review of HPV-Related Head and Neck Cancer, *J Clin Med*. 7 (9) (2018) pii: E241. DOI:10.3390/jcm7090241
4. N. Riaz, L.G. Morris, W. Lee, T.A. Chan, Unraveling the molecular genetics of head and neck cancer through genome-wide approaches, *Genes Dis.* 1 (1) (2014) 75-86. DOI:10.1016/j.gendis.2014.07.002
5. C.H. Chung, Q. Zhang, C.S. Kong, J. Harris, E.J. Fertig, P.M. Harari, et al, P16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma, *J Clin Oncol.* 32 (35) (2014) 3930-8. DOI:10.1200/JCO.2013.54.5228
6. R. Dok, S. Nuyts. HPV⁺ Head and Neck Cancers. Molecular Pathogenesis and Evolving Treatment Strategies, *Cancers(Basel)*. 8 (4) (2016) pii: E41. DOI:10.3390/cancers8040041
7. V. Paidpally, A. Chirindel, S. Lam, N. Agarwal, H. Quon, R.M. Subramaniam, FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma, *Imaging Med.* 4 (6) (2012) 633-647. DOI:10.2217/im.12.60
8. B.F. Clem, J.O'Neal, A.C. Klarer, S. Telang, J. Chesney, Clinical development of cancer therapeutics that target metabolism, *QJM.* 109 (6) (2016) 367-72. DOI:10.1093/qjmed/hcv181
9. K.K. Ang, J. Harris, R. Wheeler, R. Weber, D.I. Rosenthal, et al, Human papillomavirus and survival of patients with oropharyngeal cancer, *N Eng J Med.* 363 (1) (2010) 24-35. DOI:10.1056/NEJMoa0912217
10. Y.S. Jung, A.J. Najy, W. Huang, S. Sethi, M. Snyder, W. Sakr, et al., HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer, *Oncotarget.* 8 (31) (2017) 51530-51541. DOI:10.18632/oncotarget.17887

11. T.W. Meijer, J.H. Kaanders, P.N. Span, J. Bussink, Targeting Hypoxia , HIF-1 , and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy, *Clin Cancer Res.* 18 (20) (2012) 5585-94. DOI:10.1158/1078-0432.CCR-12-0858
12. B. Ruttkay-nedecky, A.M. Jimenez Jimenez, L. Nejdl, D. Chudobova, J. Gumulec, et al, Relevance of infection with human papillomavirus : The role of the p53 tumor suppressor protein and E6/E7 zinc finger proteins(Review), *Int J Oncol.* 43 (6) (2013) 1754-62. DOI:10.3892/ijo.2013.2105
13. P. Sen, P. Ganguly, N. Ganguly, Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer (Review), *Oncol Lett.* 15(1) (2018) 11-22. DOI:10.3892/ol.2017.7292
14. N.S.L. Yeo-teh, Y. Ito, S. Jha, High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis, *Int J Mol Sci.* 19(6) (2018) 1706. DOI:10.3390/ijms19061706
15. C. Pan, N. Issaeva, W.G. Yarbrough, HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis, *Cancers Head Neck.* 3 (2018). DOI:10.1186/s41199-018-0039-3
16. L.M. Silva, L.C. Farias, C.A. De Carvalho Fraga et al., HPV 16/18 detection does not affect the prognosis of head and neck squamous cell carcinoma in younger and older patients, *Oncol. Lett.* 3(4) (2102) 945-949. DOI: 10.3892/ol.2012.588
17. P. Boscolo-Rizzo, A. Del-Mistro, F. Bussu, V. Lupato, L. Baboci, G. Almadori, M.C. Da Mosto, G. Paludetti, New insights into human papilloma-associated head and neck squamous cell carcinoma, *Acta Otorhinolaryngol Ital.* 33 (2) (2013) 77-87.
18. L. Sepiashvili, J.P. Bruce, S.H. Huang, B.C. Sullivan, F.F. Liu, T. Kislinger, Novel Insights into Head and Neck Cancer using Next-Generation "Omic" Technologies, *Cancer Res.* 75 (3) (2015) 480-6. DOI:10.1158/0008-5472.CAN-14-3124
19. M.L. Gillison, Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination, *J Adolesc Health.* 43(4 suppl) (2008) S52-60. DOI:10.1016/j.adohealth.2008.07.001
20. S. Elrefaey, M.A. Massaro, S. Chiocca, F. Chiesa, M. Ansarin, HPV in oropharyngeal cancer: the basics to know in clinical practice, *Acta Otorhinolaryngol Ital.* 34 (5) (2014) 299–309.
21. A. Cruz-Gregorio, I. Martínez-Ramírez, J. Pedraza-Chaverri, M. Lizano, Reprogramming of energy metabolism in response to radiotherapy in head and neck squamous cell carcinoma, *Cancers (Basel).* 11 (2) (2019) pii= E182. DOI:10.3390/cancers11020182
22. C. Fakhry, M.L. Gillison, Clinical Implications of Human Papillomavirus in Head and Neck Cancers, *J Clinical Oncol.* 24 (17) (2006) 2606-2611. DOI:10.1200/JCO.2006.06.1291
23. M. Parfenov, C. Sekhar N. Gehlenborg, S.S. Freeman, L. Danilova, et al., Characterization of HPV and host genome interactions in primary head and neck cancers. *Proc Natl Acad Sci U.S.A.* 111 (43) (2014) 15544-9. DOI: 10.1073/pnas.1416074111
24. N. Agrawal, M.J. Frederick, C.R. Pickering, C. Bettegowda, K. Chang, R.J. Li, C. Fakhry, et al., Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1, *Science.* 333(6046) (2011) 1154-7. DOI:10.1126/science.1206923
25. N. Stransky, A.M. Egloff, A.D. Tward, A.D. Kostic, K. Cibulskis, A. Sivachenko, G.V. Kryukov, et al., The mutational landscape of head and neck squamous cell carcinoma, *Science.* 333(6046) (2011)1157-60. DOI: 10.1126/science.1208130
26. F. Faraji, M. Zaidi, C. Fakhry, D.A. Gaykalova, Molecular mechanisms of human papilloma-virus related carcinogenesis in head and neck cancer, 19(9-10) (2017) 464-475. DOI:10.1016/j.micinf.2017.06.001
27. S. Wagner, N. Würdemann, C. Hübbers, M. Reuschenbach, E.S. Prigge, G. Wichmann, J. Hess, A. Dietz, M. Dürst, I. Tinhofer. et al., HPV-associated head and neck cancer: Mutational

- signature and genomic aberrations, *HNO*. 63 (11) (2015) 758-67. DOI:10.1007/s00106-015-0074-x
28. J.P. Klussmann, J.J. Mooren, M. Lehnert, S.M. Claessen, M. Stenner, C.U. Huebbers, J.S. Weissenborn, et al., Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications, *Clin. Cancer Res.* 15 (5) (2009) 1779-86. DOI:10.1158/1078-0432.CCR-08-1463
  29. S.J. Smeets, B.J. Braakhuis, S. Abbas, P.J. Snijders, B. Ylstra, et al., Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus, *Oncogene*. 25 (17) (2006) 2558-64. DOI:10.1038/sj.onc.1209275
  30. M. Lechner, G.M. Frampton, T. Fenton, A. Feber, G. Palmer, et al., Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors, *Genome Med.* 5(5) (2013). DOI:10.1186/gm453
  31. J. Carlos de Vicente, L.M. Junquera Gutiérrez, A.H. Zapalero, M.F. Fresno Forcelledo, G. Hernández-Vallejo, J.S. López Arranz, Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases, *Head Neck*. 26(1) (2004) 22-30. DOI:10.1002/hed.10339
  32. M. Lawrence, C. Sougnez, L. Lichtenstein, K. Cibulskis, et al., Comprehensive genomic characterization of head and neck squamous cell carcinomas, *Nature*. 517 (7536) (2015) 576-582. DOI:10.1038/nature14129
  33. T.Y. Seiwert, Z. Zuo, M.K. Keck, A. Khattri, C.S. Reddamallu, T. Stricker, C. Brown, et al., Integrative and comparative genomic analysis of HPV+ and HPV- head and neck squamous cell carcinomas, *Clin. Cancer Res.* 21 (3) (2015) 632-41. DOI:10.1158/1078-0432.CCR-13-3310
  34. W. Sun, J.A. Califano, Sequencing the head and neck cancer genome: implications for therapy, *Ann N Y Acad Sci.* (2014) 33-42. DOI: 10.1111/nyas.12599
  35. R.J. DeBerardinis, N.S. Chandel, Fundamentals of cancer metabolism, *Sci. Adv.* 2 (5) (2016) e1600200. DOI:10.1126/sciadv.1600200
  36. M. Yamamoto, H. Inohara, T. Nakagawa, Targeting metabolic pathways for head and neck cancers therapeutics, *Cancer Metastasis Rev.* 36 (3) (2017) 503-514. DOI:10.1007/s10555-017-9691-z
  37. P. Bose, N.T. Brockton, J.C. Dort, Head and neck cancer: From anatomy to biology, *Int. J. Cancer*. 133 (9) (2013) 2012-23. DOI:10.1002/ijc.28112
  38. D. Kumar, Regulation of glycolysis in head and neck squamous cell carcinoma, *Postdoc J.* 5(1) (2017) 14-28. DOI:10.14304/surya.jpr.v5n1.4
  39. A. Fadaka, B. Ajiboye, O. Ojo, O. Adewale, I. Olayide, R. Emuowhochere, Biology of glucose metabolism in cancer cells. *J. Oncol. Sci.* 3 (2) (2017) 45-51. DOI:10.1016/j.jons.2017.06.002
  40. A. Cruz-gregorio, J. Manzo-merino, M.C. González-garcía, J. Pedraza-Chaverri, O.N. Medina - Campos, et al., Human Papillomavirus Types 16 and 18 Early-expressed Proteins Differentially Modulate the Cellular Redox State and DNA Damage, *Int J Biol Sci.* 14 (1) (2018) 21-35. DOI:10.7150/ijbs.21547
  41. J. Knuth, S.J. Sharma, N. Würdemann, C. Holler, K. Boyan, T. Acker, et al., Hypoxia-inducible factor-1 α activation in HPV++ve head and neck squamous cell carcinoma cell lines, *Oncotarget*, 8 (52) (2017) 89681-89691. DOI:10.18632/oncotarget.20813
  42. J.C. Jun, A. Rathore, H. Younas, D. Gilkes, V.Y. Polotsky, Hypoxia-Inducible Factors and Cancer, *Curr Sleep Med Rep.* 3 (1) (2017) 1-10. DOI:10.1007/s40675-017-0062-7
  43. H. Harada, Hypoxia-inducible factor 1 – mediated characteristic features of cancer cells for tumor radioresistance, *J Radiat Res.* (2016) suppl 1:i99-i105. DOI:10.1093/jrr/rww012

44. J.E. Swartz, A.J. Pothan, I. Stegeman, S.M. Willems, W. Grolman, Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: A systematic review, *Cancer Med.* 4 (7) (2015) 1101–1116. DOI:10.1002/cam4.460
45. G.L. Semenza, Involvement of Hypoxia-Inducible Factor 1 in Human Cancer, *Intern Med.* 41 (2) (2002) 79–83. DOI:10.2169/internalmedicine.41.79
46. G.L. Semenza, HIF-1 - upstream and downstream of cancer metabolism, *Curr Opin Genet Dev.* 20 (1) (2010) 51–6. DOI:10.1016/j.gde.2009.10.009
47. I. Martinez-Ramirez, A. Carrillo-garcia, A. Contreras-paredes, E. Ortiz-sanchez, A. Cruz-gregorio, M. Lizano, Regulation of Cellular Metabolism by High-Risk Human Papillomaviruses, *Int J Mol Sci.* 19 (7) (2018) pii: E1839. DOI:10.3390/ijms19071839
48. S.P. Mathupala, A. Rempel, P.L. Pedersen, Glucose Catabolism in Cancer Cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions, *J Biol Chem.* 276(46) (2001) 43407–12. DOI:10.1074/jbc.M108181200
49. P.H. Maxwell, G.U. Dachs, J.M. Gleadle, L.G. Nicholls, A.I. Harris, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth, *Proc. Natl. Acad. Sci. U. S. A.* 94 (15) (1997) 8104–9. DOI:10.1073/pnas.94.15.8104
50. B.L. Ebert, J.D. Firth, P.J. Ratcliffe, Hypoxia and Mitochondrial Inhibitors Regulate Expression of Glucose Transporter-1 via Distinct Cis-acting Sequences, *J Biol Chem.* 270(49) (1995) 29083–29089. DOI:10.1074/jbc.270.49.29083
51. J.D. Firth, B.L. Ebert, P.J. Ratcliffe, Hypoxic Regulation of Lactate Dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements, *J Biol Chem.* 270 (36) (1995) 21021–27. DOI:10.1074/jbc.270.36.21021
52. J.W. Kim, P. Gao, Y.C. Liu, G.L. Semenza, C.W. Dang, Hypoxia- Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1, *Mol Cell Biol.* 27(21) (2007) 7381–7393. DOI:10.1128/MCB.00440-07
53. R.C. Chai, D. Lambie, M. Verma, C. Punyadeera, Current trends in the etiology and diagnosis of HPV-related head and neck cancers, *Cancer Med.* 4 (4) (2015) 596–607. DOI:10.1002/cam4.424
54. S. Mazurek, W. Zwerschke, P. Jansen-dürr, E. Eigenbrodt, Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex, *Biochem. J.* 356 (Pt 1) (2001) 247–256. DOI:10.1042/0264-6021.3560247
55. N.C. Denko, Hypoxia, HIF and glucose metabolism in the solid tumour, *Nat. Rev. Cancer.* 8 (9) (2008) 705–713. DOI:10.1038/nrc2468
56. A. Nagao, M. Kobayashi, S. Koyasu et al., HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer cells and Its Therapeutic Significance, 20(2) (2019). DOI: 10.3390/Ijms20020238
57. V. Rodolico, W. Arancio, M.C. Amato, F. Aragona, F. Cappello, O. Di Fede, et al., Hypoxia inducible factor-1 alpha expression is increased in infected +ve HPV16 DNA oral squamous cell carcinoma and +vely associated with HPV16 E7 oncoprotein, *Infect. Agent. Cancer.* 6 (1) (2011). DOI:10.1186/1750-9378-6-18
58. M. Casterland, K. Lakhan, Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in cancer cells, *Asian Pacific J Cancer Prev.* 19(9) (2018), 2377–2390. DOI: 10.22034/APJCP.2018.19.9.2377.
59. A.T. Wafaa, P.D. Tina, M.K. Rakad, R.F. Nicholas, Hypoxia-Modified Cancer Cell Metabolism, *Front Cell Dev Biol.* (2019). DOI: 10.3389/fcell.2019.00004
60. G.B. Marius, E. Jutta, E.K. Ilhem, D. Yuliya, I. Kristian, M.S. Desiree, Cuurent relevance of hypoxia in head and neck cancer, *Oncotarget,* 7(31) (2016) 50781–50804. DOI: 10.18632/oncotarget.9549.

61. Ge. Zhou, Z. Liu, J.N. Myers, TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response, *J Cell Biochem.* 117 (12) (2016) 2682–2692. DOI:10.1002/jcb.25592
62. K. Adekola, S.T. Rosen, M. Shanmugam, Glucose transporters in cancer metabolism, *Curr Opin Oncol.* 24 (6) (2012) 650–4. DOI:10.1097/CCO.0b013e328356da72
63. P.B. Ancey, C. Contat, E. Meylan, Glucose transporters in cancer – from tumor cells to the tumor microenvironment, *FEBS J.* 285 (16) (2018) 2926–2943. DOI:10.1111/febs.14577
64. M.A. Kocdor, H. Kocdor, J.S. Pereira, J.E. Vanegas, I.H. Russo, J. Russo, Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis. *Clin Transl Oncol.* 15 (1) (2013) 55–64. DOI:10.1007/s12094-012-0882-3
65. F. Schwartzenberg-Bar-Yoseph, M. Armoni, E. Karnieli, The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression, *Cancer Res.* 64 (7) (2004) 2627–33. DOI:10.1158/0008-5472.can-03-0846
66. R. Fan, W.J. Hou, Y.J. Zhao, S.L. Liu, X.S. Qui, E.H. Wang, G.P. Wu, Overexpression of HPV16 E6 / E7 mediated HIF-1 α upregulation of GLUT1 expression in lung cancer cells, *Tumour Biol.* 37 (4) (2016) 4655–63. DOI:10.1007/s13277-015-4221-5
67. N. Leiprecht, C. Munoz, I. Alesutan, G. Siraskar, M. Gopjani, et al., Regulation of Na⁺-coupled glucose carrier SGLT1 by human papillomavirus 18 E6 protein, *Biochem. Biophys. Res. Commun.* 404 (2) (2011) 695–700. DOI:10.1016/j.bbrc.2010.12.044
68. J.D. Coppock, J.H. Lee, mTOR, metabolism, and the immune response in HPV-+ve head and neck squamous cell cancer, *World J. Otorhinolaryngol. Head Neck Surg.* 2 (2) (2016) 76–83. DOI:10.1016/j.wjorl.2016.05.010
69. C.C. Tseng, T.W. Chen, Y.K. Jenq, L.Y. Tseng, J.L. Pei, P.W. Cheng, L.C. Yih, Clinical characteristics and treatment outcome of oropharyngeal squamous cell carcinoma in an endemic betel quid region, *Sci Rep.* (2020) DOI: 10.1038/s41598-019-57177-1.
70. D.J. Roberts, S. Miyamoto, Hexokinase II integrates energy metabolism and cellular protection : Acting on mitochondria and TORC1 to autophagy, *Cell Death Differ.* 22 (2) (2015) 248–57. DOI:10.1038/cdd.2014.173
71. M. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg effect: The metabolic Requirements of cell proliferation, *Science.* 324 (5930) (2009) 1029–33. DOI:10.1126/science.1160801
72. J. Mims, N. Bansal, M.S. Bhardwaj, X. Chen, A.J. Molina, A.W. Tsang, C.M. Furdul, Emergency metabolism in a matched model of radiation resistance for head and neck squamous cell cancer, *Radiat Res.* 183 (3) (2015) 291–304. DOI:10.1667/RR13828.1
73. N. Majewski, V. Noggin, P. Bhaskar, P.E. Coy, J.E. Skeen, et al., Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak, *Mol. Cell.* 16 (5) (2004) 819–30. DOI:10.1016/j.molcel.2004.11.014
74. K. Gottlob, N. Majewski, S. Kennedy, E. Kandel, R.B. Robey, N. Hay, Inhibition of early apoptotic events by Akt / PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase, *Genes Dev.* 15 (11) (2001) 1406–1418. DOI:10.1101/gad.889901
75. K.K. Arora, P.L. Pedersen, Functional significance of mitochondrial bound hexokinase in tumor cell metabolism evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP, *J Biol Chem.* 263 (33) (1988) 17422–8.
76. K. Hoppe-seyler, A. Honegger, F. Bossler, J. Sponagel, J. Bulkescher, C. Lohrey, F. Hoppe-seyler, Viral E6 / E7 oncogene and cellular hexokinase 2 expression in HPV-+ve cancer cell lines, *Oncotarget.* 8 (63) (2017) 106342–106351. DOI:10.18632/oncotarget.22463
77. H. Azoulay-zohar, A. Israelson, S. Abu-hamad, V. Shoshan-barmatz, In self-defence : hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death, *Biochem J.* 377 (Pt 2) (2004) 347–355. DOI:10.1042/BJ20031465

78. N. Majewski, V. Nogueira, R.B. Robey, N. Hay, Akt Inhibits Apoptosis Downstream of BID Cleavage via a Glucose- Dependent Mechanism Involving Mitochondrial Hexokinases, *Mol Cell Biol.* 24 (2) (2004) 730–740. DOI:10.1128/MCB.24.2.730-740.2004
79. J.C. Fleming, J. Woo, K. Moutasim, M. Mellone, S.J. Frampton, et al. HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma, *Br. J. Cancer.* 120 (3) (2019) 356–367. DOI:10.1038/s41416-018-0364-7
80. H. Yang, J.T. Zhong, S.H. Zhou, H.M. Han, Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer, *Oncotarget.* 10 (32) (2019) 3066–3083. DOI:10.18632/oncotarget.24684
81. Y. Liu, T. Murray-stewart, R.A. Jr Casero, I. Kagiampakis, L. Jin, J. Zhang, et al., Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth, *Int J Oncol.* 50 (6) (2017) 2011–2023. DOI:10.3892/ijo.2017.3979
82. Q. Zeng, J. Chen, Y. Li, K.D. Werle, R.X. Zhao, et al., LKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism, *Oncogene.* 36 (9) (2017) 1245–1255. DOI:10.1038/onc.2016.290
83. R. Kuner, M. Vogt, H. Sultmann, A. Bunes, S. Dymalla, et al., Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses, *J Mol Med (Berl).* 85 (11) (2007) 1253–62. DOI:10.1007/s00109-007-0230-1
84. J.W. Kim, P. Gao, Y.C. Liu, G.L. Semenza, C.V. Dang, Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1, *Mol. Cell. Biol.* 27 (21) (2007) 7381–93. DOI:10.1128/MCB.00440-07
85. Y.A. Fouad, C. Aanei, Revisiting the hallmarks of cancer, *Am J Cancer Res.* 7 (5) (2017) 1016–1036.
86. T. Veldman, X. Liu, H. Yuan, R. Schlegel, Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter, *Proc. Natl. Acad. Sci. U. S. A.* 100 (14) (2003) 8211–8216. DOI:10.1073/pnas.1435900100
87. L. Yu, X. Chen, X. Sun, L. Wang, S. Chen, The glycolytic switch in Tumors: How Many Players Are Involved? *J Cancer.* 8 (17) 2017 3430–3440 DOI:10.7150/jca.21125
88. M.V. Liberti, J.W. Locasale, The Warburg Effect : How Does it Benefit Cancer Cells ?, *Trends Biochem Sci.* 41 (3) (2016) 211–218. DOI:10.1016/j.tibs.2015.12.001
89. L.Yu, X. Chen, L. Wang, S. Chen, Oncogenic virus-induced aerobic glycolysis and tumorigenesis, *J Cancer.* 9 (20) (2018) 3699–3706. DOI:10.7150/jca.27279
90. V.R. Fantin, J. St-Pierre, F. Leder, Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance, *Cancer Cell.* 9 (6) (2006) 425–434. DOI:10.1016/j.ccr.2006.04.023
91. H. Shim, C. Dolde, B.C. Lewis, C.S. Wu, G. Dang, et al., c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth, *Proc Natl Acad Sci U S A.* 94 (13) (1997) 6658–63. DOI:10.1073/pnas.94.13.6658
92. H. Xie, V.A Valera, M.J Merino, A.M. Amato, S. Signoretti, et al., LDH-A Inhibition, a therapeutic strategy for treatment of Hereditary Leiomyomatosis and Renal Cell Cancer, *Mol Cancer Ther.* 8(3) (2009) 626–635. DOI:10.1158/1535-7163.MCT-08-1049
93. Y. Feng, Y. Xiong, T. Qiao, X. Li, L. Jia, Y. Han, Lactate dehydrogenase A : A key player in carcinogenesis and potential target in cancer therapy, *Cancer Med.* 7 (12) (2018) 6124–6136. DOI:10.1002/cam4.1820
94. D. Mishra, D. Banerjee, Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment, *Cancers(Basel).* 11 (6) (2019) pii:E750. DOI:10.3390/cancers11060750

95. R.J. Gillies, I. Robey, R.A. Gatenby, Causes and Consequences of Increased Glucose Metabolism of Cancers, *J Nucl Med.* (2008) 24S-42S. DOI:10.2967/jnumed.107.047258
96. F. Hirschhaeuser, U.G. Sattler, W. Mueller-kliesser, Lactate : A Metabolic Key Player in Cancer, *Cancer res.* 71 (22) (2011) 6921–5. DOI:10.1158/0008-5472.CAN-11-1457
97. K. Fischer, P. Hoffmann, S. Voelkl, N. Meidenbauer, et al., Inhibitory effect of tumor cell – derived lactic acid on human T cells, *Blood.* 109 (9) (2007) 3812–9. DOI:10.1182/blood-2006-07-035972
98. K. Goetze, S. Walenta, M. Ksiazkiewicz, L.A. Kunz-schughart, W. Mueller-kliesser, Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release, *Int J Oncol.* 39 (2) (2011) 453–63. DOI:10.3892/ijo.2011.1055
99. M.R. Castellanos, Q. Pan, p53 therapies for head and neck cancer, *World J. Otorhinolaryngol. Neck Surg.* 2 (2) (2016) 68– 75. DOI:10.1016/j.wjorl.2016.05.005
100. N. Kindt, G. Descamps, J.R. Lechien, M. Remmelink, J.M. Colet, et al., Involvement of HPV Infection in the Release of Macrophage Migration Inhibitory Factor in Head and Neck Squamous Cell Carcinoma, *J Clin Med.* 8 (1) (2019) pii:E75. DOI:10.3390/jcm8010075
101. B. Jiang, Aerobic glycolysis and high level of lactate in cancer metabolism and microenvironment, *Genes Dis.* 4(1) (2017) 25–27. DOI:10.1016/j.gendis.2017.02.003
102. K. Nadege, D. Geraldine, R.L. Jerome, R. Myriam et al., Involvement of HPV Infection in Release of Macrophage Migration Inhibitory Factor in Head and Neck Squamous Cell Carcinoma, *J Clin Med.* 8(1) (2019) DOI: 10.3390/jcm8010075.
103. J.C. Fleming, J. Woo, K. Moutasim, M. Mellone, S.J. Frampton, et al. HPV , tumour metabolism and novel target identification in head and neck squamous cell carcinoma, *Br. J. Cancer.* 120 (3) (2019) 356-367. DOI:10.1038/s41416-018-0364-7
104. L. Dang, D.W. White, S. Gross, B.D. Tennett, et al., Cancer- associated IDH1 mutations produce 2-hydroxyglutarate, *Nature.* 462 (7274) (2009) 739-44. DOI:10.1038/nature08617
105. B.E. Baysal, R.E. Ferrell, J.E. Willett-Brick, E.C. Lawrence, et al., Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma, *Science.* 287 (5454) (2000) 848-51. DOI:10.1126/science.287.5454.848
106. I.P. Tomlinson, N.A. Alam, A.I. Rowan, E. Barclay, et al., Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer the multiple leiomyoma consortium, *Nat. Genet.* 30 (4) (2002) 406-10. DOI:10.1038/ng849
107. D.A. Tennant, R.V. Durán, F. Gottlieb Targeting metabolic transformation for cancer therapy. *Nat. Rev. Cancer,* 10 (4) (2010) 267-77. DOI:10.1038/nrc2817
108. M. Yuneva, N. Zamboni, P. Oefner, R. Sachidanandam, Y. Lazebnik, Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells, *J. Cell Biol.* 178 (1) (2007) 93–105. DOI:10.1083/jcb.200703099
109. Y. Chendong, J. Sudderth, D. Tuyen, R.G. Bachoo, J.G. McDonald, R.J. DeBerardinis , Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signalling, *Cancer Res.* 69 (20) (2009) 7986-93. DOI:10.1158/0008-5472.CAN-09-2266
110. M.C. Matrk, M. Watanabe, R. Muraleedharan, P.F. Lambert, et al., Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis, *PLoS One.* 12 (5) (2017) e0177952. DOI:10.1371/journal.pone.0177952
111. Y. Zhu, T. Li, S.R. Da Silva, J.J. Lee, C. Lu, et al., A critical role of glutamine and asparagine γ -Nitrogen in nucleotide biosynthesis in cancer cells hijacked by an oncogenic virus, *mBio.* 8 (4) (2017) pii: e01179-17. DOI:10.1128/mBio.01179-17

- 112.A.R. Mullen, W.W. Wheaton, E.S. Jin, P.H. Chen, et al., Reductive carboxylation supports growth in tumour cells with defective mitochondria, *Nature*. 481 (7381) (2012) 385–388. DOI:10.1038/nature10642
- 113.V.C. Sandulache, T.J. Ow, C.R. Pickering, M.J. Frederick, et al., Glucose, Not Glutamine ,is the Dominant Energy Source Required for Proliferation and Survival of Head and Neck Squamous Carcinoma Cells, *Cancer* 117 (13) (2011) 2926- 38. DOI:10.1002/cncr.25868
- 114.D. Martinez-Zapien, F.X. Ruiz, J. Poirson, A. Mitschler, et al., Structure of the E6/E6AP/p53 complex required for HPV- mediated degradation of p53, *Nature*. 529 (7587) (2016) 541-5. DOI:10.1038/nature16481
- 115.P.M. Hwang, F. Bunz, J. Yu, C. Rago, T.A. Chan, et al., Ferredoxin reductase affects p53-dependent, 5- fluorouracil-induced apoptosis in colorectal cancer cells, *Nat. Med.* 7 (10) (2001) 1111-7. DOI:10.1038/nm1001-1111
- 116.S. Matoba, J.G. Kang, W.D. Patino, A. Wragg, et al., p53 regulates mitochondrial respiration, *Science* 312 (5780) (2006)1650-3. DOI:10.1126/science.1126863
- 117.S. Zhang, M.W. Hulver, R.P. McMillan, M.A. Cline, E.R. Gilbert. The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility, *Nutr. Me ab (Lond).* 11 (1) (2014). DOI:10.1186/1743-7075-11-10
- 118.Y. Wen, Maxwell's demon at work: Mitochondria, the organelles that convert information into energy?, *Chronic Dis. Transl. Med.* 4 (2) (2018)135–136. DOI:10.1016/j.cdtm.2018.05.002
- 119.P. Maeckler, S. Carobbio, B. Rubi, In beta-cells, mitochondria integrate and generate metabolic signals controlling insulin secretion, *Int. J. Biochem. Cell Biol.* 38 (5-6) (2006) 696-709. DOI:10.1016/j.biocel.2005.12.006
- 120.L.M. Pinatti, H.M. Walline, T.E. Carey, Huria. Papillomavirus Genome Integration and Head and Neck Cancer, *J. Dent. Res.* 97 (6) (2018) 691-700. DOI:10.1177/0022034517744213
- 121.E. vastová, N. Žilka, M. Zat'ovičová, A. Cibadulinová, et al., Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β -catenin, *Exp. Cell Res.* 290 (2) (2003) 332-45. DOI:10.1016/S0014-4827(03)00351-3
- 122.J.M. Spangle, K. Munger, The Human Papillomavirus Type 16 E6 Oncoprotein Activates mTORC1 Signaling and Increases Protein Synthesis, *J. Virol.* 84 (18) (2010) 9398- 407. DOI: 10.1128/JVI.00974-10.
- 123.L. Zheng, H. Ding, Z. Lu, Y. Li, et al., E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6, *Genes Cells.* 13 (3) (2008) 285-94. DOI:10.1111/j.1365-2443.2003.01162.x
- 124.T.A. Day, K. Shirai, I.E. O'Brien, M.G. Matheus, et al. Inhibition of mTOR signaling and clinical activity of rapamycin in head and neck cancer in a window of opportunity trial, *Clin. Cancer Res.* 25 (4) (2019) 1156-1164. DOI: 10.1158/1078-0432.CCR-18-2024.
- 125.A.K. Gupta, J.H. Lee, W.W. Wilke, H. Quon, et al., Radiation Response in Two HPV-Infected Head-and-Neck Cancer Cell Lines in Comparison to a Non-HPV-Infected Cell Line and Relationship to Signaling Through AKT, *Int. J. Radiat. Oncol. Biol. Phys.* 74 (3) (2009) 928-33. DOI:10.1016/j.ijrobp.2009.03.004
- 126.E. Racker, R.J. Resnick, R. Feldman, Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes, *Proc. Natl. Acad. Sci. U. S. A.* 82 (11) (1985) 3535-8. DOI: 10.1073/pnas.82.11.3535
- 127.K. Kawauchi, K. Araki, K. Tobiume, N. Tanaka, p53 regulates glucose metabolism through an IKK-NF- κ B pathway and inhibits cell transformation, *Nat. Cell Biol.* 10 (5) (2008) 611-8. DOI: 10.1038/ncb1724
- 128.Y. Tang, H. Kwon, B.A. Neel, M. Kasher-Meron, et al., The fructose-2,6-bisphosphatase TIGAR suppresses NF-B signaling by directly inhibiting the linear ubiquitin assembly complex LUBAC. *J. Biol. Chem.* 293 (20) (2018) 7578- 7591. DOI: 10.1074/jbc.RA118.002727

- 129.P. Jiang, W. Du, X. Wang, A. Mancuso, et al., P53 regulates biosynthesis through direct inactivation of glucose-6- phosphate dehydrogenase, *Nat. Cell Biol.* 13 (3) (2011) 310-6. DOI: 10.1038/ncb2172
- 130.E.M. Hammond, A.J Giaccia, Hypoxia-Inducible Factor-1 and p53: Friends, Acquaintances, or Strangers?. *Clin. Cancer Res.* 12 (17) (2006) 5007-9. DOI:10.1158/1078-0432.CCR-06-0613
- 131.T.A. Baudino, C. Mckay, H. Pendeville-samain, J.A. Nilsson, et al., c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression, *Genes Dev.* 16 (19) (2002) 2530–2543. DOI:10.1101/gad.1024602
- 132.S. Graham, H. Dayal, T.Rohrer, M.Swanson, H.Sultz, D. Shedd, S. Fischman, Dentition, diet, tobacco, and alcohol in the epidemiology of oral cancer, *J Natl Cancer Inst.* (1977) 59:1611-1618. DOI:10.1093/jnci/59.6.1611.
- 133.C.J. Stewart, T.A.Auchtung, N.J. Ajami, et al., Effects of tobacco smoke and electronic cigarette vapour exposure on the oral and gut microbiota in humans: a pilot study. *Peer J.* (2018) 6:e4693. DOI: 10.7717/peerj.4693.
- 134.A.K. Sharma, W.T. DeBusk, I. Stepanov, A. Gomez, S S Khariwala, Oral Microbiome Profiling in Smokers with and without Head and Neck Cancer reveals Variations Between Health and Disease. *Cancer Prev Res (Phila).* (2020) 13(5):463-474. DOI: 10.1158/1940-6207.CAPR-19-0459.
- 135.D. Bornigen, B. Ren, R. Pickard, et al., Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer. *Sci Rep.* (2017), 7:17686. DOI: 10.1038/s41598-017-17795-z.
- 136.J.R. Marshall, S. Graham, B.P Haughey, et al. Smoking, alcohol and diet in the epidemiology of oral cancer. *Eur J Cancer B Oral Oncol.* (1992) 28B:9-15. DOI:10.1016/0964-1955(92)90005-I
- 137.S.A. Agarwal, R.V. Vijayalekshmi, B. Surg, Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. *Clin Cancer Res.* (2009) 15:425-430. DOI:10.1158/1078-0432.CCR-08-0142.
- 138.F.E. Dewhirst, T. Chen, J. Izard, B. J. Paster, A.C. Tanner, W.H. Yu, A. Lakshmanan, W.G. Wade, The human oral microbiome. *J Bacteriol.* (2010) 192:5002-5017. DOI:10.1128/JB.00542-10.
- 139.M.C. Petralia, E. Mazzon, M. Fagone, L. Falzone, P. Bramanti, F. Nicoletti, M.S. Basile, Retrospective follow-up analysis of the transcriptomic patterns of cytokines, cytokine receptors and chemokines at preception and during pregnancy, in women with post-partum depression, *Exp Ther Med.* (2019), 18:2055-2062. DOI:10.3892/etm.2019.7774.
- 140.J. Katz, S. Wallet, S. Cha, Periodontal disease and the oral-systemic connection: is it all the RAGE? *Quintessence Int.*, (2010) 41:229-237.
- 141.G. Zhang, S. Ghosh, Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysachharide through Toll-like receptors, *J Endotoxin Res.* (2000) 6:453-457. DOI: 10.1179/096805100101532414.
- 142.T.M. Karpinski, Role of oral microbiota in cancer development. *Microorganisms.* (2019) 7:E20. DOI:10.3390/microorganisms7010020.
- 143.G.R.M. La Rosa, G. Gattuso, E. Pedulla, E. Rapisarda, N. Daria, Association of oral dysbiosis with oral cancer development (Review), *Oncol. Lett* (2020) 3045-3058. DOI: 10.3892/ol.2020.11441.
- 144.P.E. Kolenbrander, R.N. Andersen, D.S. Blehert, P.G. Eglund, J.S. Foster, R.J.J. Jr. Palmer, Communication among oral bacteria, *Microbiol Mol Biol Rev.* (2002) 66:486-502. DOI:10.1128/MMBR.66.3.486-5-5.2002.
- 145.R. Leonardi, C. Loreto, E. Barbato, A. Polimeni, R. Caltabiano, L. Lo Muzio, A histochemical survey of the human temporomandibular joint disc of patients with internal derangement without reduction. *J Craniofac Surg.* (2007) 18:1429–1433. 20. DOI:10.1097/scs.0b013e1814fb72a.

- 146.M.L. Gillison, A.K. Chaturvedi, D.R. Lowy, HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women, *Cancer*. 113 (10 suppl) (2008) 3036-46. DOI: 10.1002/cncr.23764
- 147.S.V. Graham, Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies, *Future Microbiol.* 5(10), 1493-1506. DOI: 10.2217/fmb.10.107.
- 148.J.M. Gottesfeld, C. Melander, R.K. Suto, H. Raviol, et al. Sequence-specific recognition of DNA in the nucleosome by pyrrole-imidazole polyamides, *J. Mol. Biol.* 309 (3) (2001) 615-29. DOI:10.1006/jmbi.2001.4694
- 149.J.A. Bonner, P.M. Harari, J. Giralt, R.B. Cohen, et al., Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival, *Lancet Oncol.* 11 (1) (2010) 21-8. DOI: 10.1016/S1470-2045(09)70311-0
- 150.B. Miles, H.P. Safran, B.J. Monk, Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001, *Gynecol. Oncol. Res. Pract.* (2017) 4:10. DOI: 10.1186/s40661-017-0047-8
- 151.A.K. Chaturvedi, E.A. Engels, R.M. Pfeiffer et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States, *J. Clin. Oncol.* 29 (32) (2011) 4294-301. DOI:10.1200/JCO.2011.36.4596
- 152.A. Janzer, N.J. German, K.N. Gonzalez-herrera, J.M. Asara, et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells, *Proc Natl Acad Sci U S A.* 111 (29) (2014) 10574-9. DOI: 10.1073/pnas.1409844111
- 153.C.T. Lucido, J.L. Callejas-Valera, P.L. Colbert, D.W. Vermeer, et al., β 2-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+ve) HNSCC, *Oncogenesis*, 7 (10) (2018). DOI: 10.1038/s41389-018-0090-2
- 154.T.L. Christopher, L.C.V. Juan, L.C. Paul, et al., β 2-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC, *Oncogenesis*, 7(10) (2018) DOI: 10.1038/s41389-018-0090-2.
- 155.X. Zhang, M. Fryknäs, E. Herrlund, W. Fayad, A. De Milito, et al., Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments, *Nat. Commun.* (2014) 5: 3295. DOI: 10.1038/ncomms4295
- 156.A.L. Simons, M.A. Fathallah, L.M. Mattson, B.J. Smith et al, Enhanced Response of Human Head and Neck Cancer Xenograft Tumors to Cisplatin Combined With 2-Deoxy- d-Glucose Correlates With Increased 18F-FDG Uptake as Determined by PET Imaging, *Int. J. Radiat. Oncol. Biol. Phys.* 69 (4) (2007) 1222-30. DOI:10.1016/j.ijrobp.2007.07.2343
- 157.R. Yogesh, Y. Priyanshu, K. Neeraj, K. Namita, B. Anant Narayan, Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin, *Biosci Rep.* 39 (9) (2019) pii:BSR20190880. DOI: 10.1042/BSR20190880
- 158.G.S. Krasnov, A.A. Dmitriev, V.A. Lakunina, A.A. Kirpiy, A.V. Kudryavtseva, Targeting VDAC-bound hexokinase II: A promising approach for concomitant anti-cancer therapy, *Expert Opin. Ther. Targets.* 17 (10) (2013) 1221-33. DOI: 10.1517/14728222.2013.833607
- 159.X. Sun, L. Zhang, MicroRNA-143 suppresses oral squamous cell carcinoma cell growth , invasion and glucose metabolism through targeting hexokinase 2 . *Biosci Rep.* 37 (3) (2017) pii:BSR20160404. DOI: 10.1042/BSR20160404
- 160.D. Catanzaro, S. Nicolosi, V. Cocetta, M. Salvalaio, et al. Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells, *Oncotarget.* 9 (24) (2018) 16847-16860. DOI: 10.18632/oncotarget.24708

- 161.H. Lu, X. Li, Z. Luo, J. Liu, Z. Fan. Cetuximab reverses the warburg effect by inhibiting HIF-1-regulated LDH - A, Mol. Cancer Ther. 12 (10) (2013) 2187-99. DOI: 10.1158/1535-7163.MCT-12-1245
- 162.M. Agostini, L.Y. Almeida, D.C. Bastos, R.M. Ortega RM et al., The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas, Mol. Cancer Ther. 13 (3) (2014) 585- 95. DOI: 10.1158/1535-7163.MCT-12-1136

Figure Legends

Figure 1. Factors associated with HNSCC. Consumption of tobacco products and alcohol are the major risk factors involved in HPV⁻ HNSCC. Whereas, HPV infection mediates HPV⁺ HNSCC. The HPV⁻ HNSCC patients of younger age have a poor clinical outcome as compared to HPV⁺ HNSCC, whereas the HPV⁺ HNSCC have an improved clinical outcome. The anatomical location of HPV⁻ HNSCC involve all head and neck cancer sites, while in HPV⁺ HNSCC, the oropharyngeal region is the major site of infection. Mutation in p53 and pkb are the major reason behind HPV⁻ HNSCC, while E6 mediated inactivation of p53 and E7 mediated degradation of pRb is the major reason behind HPV⁺ HNSCC.

Figure 2. In normal cells, the glycolysis and OXPHOS are regulated in a synchronized manner. Glucose is converted to pyruvate in aerobic conditions and generates 2 ATP through glycolysis. Pyruvate is then converted to acetyl CoA and regulated in OXPHOS for the generation of total 36 ATPs. Under anaerobic condition, pyruvate is converted to lactate by LDH-A for the generation of ATP. In HNSCC cells, solid tumors favor glycolysis as compared to OXPHOS for the generation of ATP even in the presence of oxygen following Warburg phenomena. HNSCC cells shift the metabolic flow from OXPHOS to glycolysis. OXPHOS (Oxidative phosphorylation); ATP (Adenosine triphosphate); LDH (Lactate dehydrogenase).

Figure 3. In HPV⁺ Hypoxia, VHL mutation and stimulation of growth factor such as PI3K/Akt/mTOR, MAPK, EGFR causes accumulation and stabilization of HIF-1. Under hypoxia HIF1 α and HIF-1 β binds to the HRE in the DNA segment promotes the transcription of genes involved in metabolism (GLUT, HK, LDH, GADPH), regulation of pH, angiogenesis (VEGF, TGF β), proliferation(TGF α , Cyclin G2), apoptosis(BNIP3, NIX). VHL(von Hippel-Lindau); GLUT(Glucose transporter); HK(Hexokinase); LDH(Lactate dehydrogenase); G6PD (Glucose-6-phosphate dehydrogenase), VEGF (Vascular endothelial growth factor); TGF(Transforming growth factor); TGF(Transforming growth factor); BNIP3(BCL2 Interacting Protein 3).

Figure 4. HR-HPV-E6 mediated degradation of p53, upregulates the expression of GLUT1

and elevates the uptake of glucose uptake in HNSCC. SGLT Na⁺ve /glucose co-transporters through Na⁺ve /K⁺ve ATPase secondary active transport causes glucose internalization in epithelial cells. SGLT1 Na⁺ve /glucose co-transporters present in HPV⁺ HNSCC facilitates cells to accumulate glucose even in the presence of low concentrations of glucose. Highest accumulation of FDG can be detected using PET SCAN and resulting in poor patient survival.

Figure 5. HPV infection promotes glycolysis in head and neck squamous cell carcinoma. The E6 oncoproteins inhibits p53 by proteolytic degradation further activating HIF-1 which activates the glycolysis in head and neck squamous cell carcinoma. Akt/mTOR activation by E6 oncoprotein induces the high glucose metabolism promoting the cancer survival. E7 oncoprotein of the HPV activates the PKM-2 gene increasing the lactate production in the cancer cells. HPV presence, activates COX augments, upregulating ETC.

Figure 6. TIGAR, downstream target of p53 is a bi-functional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2), responsible for fructose-2,6-bisphosphate (Fru-2,6-P₂) degradation. Fru-2,6-P₂ allosterically activates PFK1 causing p53 mediated downregulation of Fru-2,6-P₂ via TIGAR, thereby inhibiting the flow of glycolysis in HNSCC cells. p53 plays a major role in PPP by glucose 6-phosphate dehydrogenase (G6PD) dependent manner inhibition. p53 have been reported to play an important role in the upregulation of HIF-1 α , resulting in the increased glycolysis, necrosis, angiogenesis contributing to cancer progression

HPV ⁺		
Drug	Target	NCT No.
Gardasil	HPV 6, 11, 16, 18	NCT00092534
Gardasil 9	16, 18, 31, 33, 45, 52, and 58;	NCT03943875
Pyrole-imidazole	A-T regions of viral genome	-
Cetuximab	EGFR receptor	NCT01084083
Axalimogene	Immune-based therapy	NCT02540928
Propranolol	Pyruvate dehydrogenase Kinase	NCT02013492
VLX600	Electron transport chain (ETC)	-
Cervarix	HPV 16, 18	NCT00316693
HPV ⁻		
Silybin	GLUT	NCT03440164
Lonidamide	HK	NCT00435448
2-Deoxyglucose	G6P isomerase	NCT00633087
TLN-232	PKM2 dimers	NCT00735332
Dichloroacetate	PDK	NCT01111097
AZD-3965	MCT1	NCT01791595
CPI-613	Pyruvate Dehydrogenase	NCT03699319
Gossypol	LDH-A	NCT00540722
Galloflavin	LDH-A	Pre-Clinical Studies
Daunorubicin	GLUT-1	NCT02914977
Gefitinib	Tyrosine Kinase	NCT00049543
Erlotinib	Tyrosine Kinase	NCT02013206

Table 1: Current therapeutic strategies for HPV⁺ and HPV⁻ HNSCC